Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Pozuelo De Alarcon – page 219

3 275 clinical trials in Pozuelo De Alarcon, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Pozuelo De Alarcon at a glance
3 275
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 275 trials in Pozuelo De Alarcon

Open in trial search

Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Study on the Safety and Effectiveness of Human Alpha1-Proteinase Inhibitor for Preventing Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplant.

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALPHA-1-ANTITRYPSIN
  • Sponsor:CSL Behring LLC

Malignant melanoma+4

Not recruiting

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Autogene Cevumeran
  • Sponsor:Genentech Inc.

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Breast cancer metastatic+1

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Cervix carcinoma

Not recruiting

Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Nivolumab and Ipilimumab with Chemotherapy for Patients with Stage IV Non-Small Cell Lung Cancer and Brain Metastases

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Fundacion GECP

Plasma cell myeloma

Not recruiting

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on TTX-030, Budigalimab, and Chemotherapy for Untreated Metastatic Pancreatic Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:Trishula Therapeutics Inc.

Study of Pegcetacoplan (APL-2) in Patients with Transplant-associated Thrombotic Microangiopathy After Stem Cell Transplantation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Pozuelo De Alarcon

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on multiple cancer types including bladder cancer, pancreatic adenocarcinoma, and non-small cell lung cancer. Studies evaluate novel combination therapies and targeted treatments.

  • Advanced solid tumors
  • Metastatic melanoma
  • Gastric cancer

Research includes immunotherapy approaches and antibody-drug conjugates for improved treatment outcomes.

02 Respiratory Medicine

Clinical investigations in respiratory conditions, including studies of RSV prevention in high-risk infants and novel treatments for uncontrolled asthma. Research focuses on innovative therapeutic approaches.

  • COVID-19 vaccine development
  • Respiratory infections
  • Inflammatory airway diseases

Studies evaluate both preventive measures and treatment interventions.

03 Neurological Disorders

Research targeting neurological conditions, with emphasis on Alzheimer's Disease and Multiple Sclerosis. Studies focus on disease-modifying therapies and novel treatment approaches.

  • Early-stage Alzheimer's treatment
  • Relapsing MS therapies
  • Neurodegeneration

Investigations aim to slow disease progression and improve patient outcomes.

04 Hematology

Studies in blood disorders including acute myeloid leukemia and immune thrombocytopenia. Research evaluates new therapeutic approaches and combination treatments.

  • Leukemia treatments
  • Myelodysplastic syndrome
  • Platelet disorders

Focus on improving survival rates and treatment efficacy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.